153 related articles for article (PubMed ID: 1026347)
1. Combined effect of cytosine arabinoside and thiopurines.
Valeriote F; Vietti T; Edelstein M
Cancer Treat Rep; 1976 Dec; 60(12):1925-34. PubMed ID: 1026347
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of both leukemic and normal cell population reduction following 5-azacytidine.
Presant CA; Vietti T; Valeriote F
Cancer Res; 1975 Aug; 35(8):1926-30. PubMed ID: 50128
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cytotoxic action of iphosphamide and cyclophosphamide.
Phelan ET; Vietti TJ; Valeriote FA; Coulter D
Anticancer Res; 1981; 1(3):149-54. PubMed ID: 7342853
[TBL] [Abstract][Full Text] [Related]
4. Biological characterization of a prolonged antileukemic effect of 5-azacytidine.
Presant CA; Valeriote F; Vietti TJ
Cancer Res; 1977 Feb; 37(2):376-81. PubMed ID: 64294
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
Presant CA; Vietti TJ; Valeriote F; Coulter DM
J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
[TBL] [Abstract][Full Text] [Related]
6. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
Kim K; Blechman WJ; Riddle VG; Pardee AB
Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
[TBL] [Abstract][Full Text] [Related]
7. Use of cell-cycle information in the preparation of drug combinations: results with cytosine arabinoside plus actinomycin D1,2.
Bhuyan BK; Fraser TJ; Day KJ
Cancer Treat Rep; 1976 Dec; 60(12):1813-8. PubMed ID: 1036090
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of 1-beta-D-arabinofuranosylcytosine and 6-thioguanine in vitro on granulocytic progenitor cells.
Greenberg PL; VanKersen I; Mosny S
Cancer Res; 1976 Dec; 36(12):4412-7. PubMed ID: 1069606
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor cell heterogeneity of a murine leukemia cell line (L1210) in response to arabinosylcytosine: quantitation using a computerized image analysis system.
Raymakers RA; Slocum HK; Minderman H; Malmberg M; Rustum YM
Exp Hematol; 1993 May; 21(5):602-7. PubMed ID: 8513859
[TBL] [Abstract][Full Text] [Related]
10. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
Rauko P; Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Schott H; Fritzer-Szekeres M; Novotny L; Szekeres T
Anticancer Res; 2003; 23(5A):3841-6. PubMed ID: 14666686
[TBL] [Abstract][Full Text] [Related]
11. Effect of the interval between high dose 1-beta-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia.
Colly LP; Peters WG; Willemze R
Cancer Res; 1986 Aug; 46(8):3825-7. PubMed ID: 3460691
[TBL] [Abstract][Full Text] [Related]
12. Histidinol-mediated enhancement of the specificity of two anticancer drugs in mice bearing leukemic bone marrow disease.
Warrington RC; Fang WD
J Natl Cancer Inst; 1985 May; 74(5):1071-7. PubMed ID: 3858576
[TBL] [Abstract][Full Text] [Related]
13. Computer simulation of leukemia therapy: combined pharmacokinetics, intracellular enzyme kinetics, and cell kinetics of the treatment of L1210 leukemia by cytosine arabinoside.
Lincoln T; Morrison P; Aroesty J; Carter G
Cancer Treat Rep; 1976 Dec; 60(12):1723-39. PubMed ID: 1026330
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
Avramis VI; Powell W
Cancer Invest; 1987; 5(4):293-9. PubMed ID: 3664332
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells.
Nakayama T; Sakamoto S; Sassa S; Suzuki S; Kudo H; Nagasawa H
Anticancer Res; 2005; 25(1A):157-60. PubMed ID: 15816533
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.
Cadman E; Eiferman F
J Clin Invest; 1979 Sep; 64(3):788-97. PubMed ID: 288743
[TBL] [Abstract][Full Text] [Related]
17. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
Burke PJ; Karp JE; Vaughan WP
J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
[TBL] [Abstract][Full Text] [Related]
19. Effect of drug combination of antitumor activity and myelotoxicity.
Fujimoto S; Inouye T; Tsukagoshi S
Gan; 1976 Apr; 67(2):207-14. PubMed ID: 964553
[TBL] [Abstract][Full Text] [Related]
20. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate.
Edelstein M; Vietti T; Valeriote F
Cancer Res; 1975 Jun; 35(6):1555-8. PubMed ID: 1131822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]